The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Central Nervous System Therapeutics Market Expected To Change From 2026 To 2030?
The central nervous system therapeutics market size has seen substantial growth in recent years. It is projected to expand from $134.99 billion in 2025 to $147.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historical period is attributable to the increasing burden of depression and epilepsy, a growing aging population, the limited treatment options available for degenerative disorders, rising hospitalization rates for cns conditions, and the expansion of hospital and clinic infrastructure.
The central nervous system therapeutics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $206.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.8%. The projected growth throughout the forecast period is primarily driven by factors such as the development of novel neuroprotective agents, the expansion of biologics and gene-based therapies, increasing investment in neuroscience research, the rising adoption of personalized medicine, and expanding access to cns treatments in emerging markets. Concurrently, major trends expected during this period include the rising prevalence of neurological and mental health disorders, the growing adoption of combination therapies for cns diseases, an increasing focus on long-term disease management and symptom control, the expansion of homecare-based cns treatment solutions, and improved drug formulations with better blood-brain barrier penetration.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27249&type=smp
What Primary Drivers Are Shaping The Central Nervous System Therapeutics Market?
The rising occurrence of mental health conditions is anticipated to fuel the expansion of the central nervous system therapeutics market in the future. These disorders encompass a wide array of conditions that influence an individual’s thinking, feelings, actions, or mood, such as depression, anxiety disorders, schizophrenia, and bipolar disorder. The growing incidence of mental health problems is attributed to heightened exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to issues like anxiety, depression, and burnout. Central Nervous System (CNS) therapeutics are instrumental in treating mental health disorders by targeting brain chemicals and neural pathways essential for mood, behavior, and cognition. For instance, in December 2025, a report published by the Bristol City Council, a UK-based local government authority, highlighted that in Bristol, 66,815 patients aged 18 and over were recorded on GP practice depression registers in 2022-23, indicating a 6.0% rise from 2021-22. Consequently, the increasing prevalence of mental health disorders is driving the growth of the central nervous system therapeutics market.
How Is The Central Nervous System Therapeutics Market Organized By Segment Classification?
The central nervous system therapeutics market covered in this report is segmented –
1) By Drug Class: Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes
2) By Disease: Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
4) By Application: Hospital, Clinic, Homecare, Other Applications
Subsegments:
1) By Anesthetics: General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics
2) By Anticonvulsants: Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents
3) By Antiemetics: Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids
4) By Central Nervous System (CNS) Stimulants: Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives
5) By Pain Relievers: Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief
6) By Other Drug Classes: Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents
What Market Trends Are Affecting The Central Nervous System Therapeutics Market?
Key companies within the central nervous system therapeutics market are prioritizing the development of innovative solutions, such as capsid engineering, to improve targeted gene delivery, therapeutic effectiveness, and blood-brain barrier penetration for more effective treatment of neurological disorders. Capsid engineering involves the modification and optimization of the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), employed in gene therapy. For instance, in May 2025, Coave Therapeutics S.A., a French biotechnology company, introduced coAAV CSF 01, a novel adeno associated virus (AAV) designed for central nervous system (CNS) delivery, utilizing their proprietary ALIGATER platform. This new vector demonstrated significantly enhanced transduction efficiency and safety when compared to AAV9. When administered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Remarkably, expression levels equivalent to AAV9 were attained at merely one-fifth of the dose, highlighting its superior potency. Additionally, the vector exhibited substantially reduced off-target expression in peripheral organs like the liver, while maintaining a favorable safety profile, including preserved peripheral nerve integrity. These outcomes underscore the vector’s potential to enhance CNS gene therapy results with greater precision and reduced systemic risk.
Who Are The Industry Participants Involved In The Central Nervous System Therapeutics Market?
Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.
Get The Full Central Nervous System Therapeutics Market Report:
Which Region Is The Top Contributor To The Central Nervous System Therapeutics Market By Share?
North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Central Nervous System Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Central Nervous System Therapeutics Market 2026, By The Business Research Company
Insurance Business Process Outsourcing Market Report 2026
Outsourced Customer Care Services Market Report 2026
Outsourced Software Testing Services Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model